Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ajay Nirula"'
Autor:
Jack Knorr, Russell Perry, Peter Chen, Corey Hebert, Richard E. Higgs, Mark D. Williams, Joseph Boscia, Bharat Mocherla, Masoud Azizad, Princy Kumar, Robert L. Gottlieb, Paul Klekotka, Dipak R. Patel, Ajay Nirula, Imad Shawa, Andra L. Blomkalns, Andrew C. Adams, Gregory D. Huhn, Kenneth L. Custer, Lei Shen, Timothy R. Holzer, Jason Morris, Philip J. Ebert, Andrew E. Schade, Jacob Van Naarden, Blaze investigators, Gerard J. Oakley, Jose Cardona, Janelle Sabo, Matan C. Dabora, Daniel Skovronsky, Chad Crystal, Barry Heller, Awawu Igbinadolor, Michael Dougan
Publikováno v:
Clinical Infectious Diseases. 75:e440-e449
Background Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment. Methods This Phase 3 portion of the BLAZE-1 tr
Autor:
Charles Benson, Emmanuel Chigutsa, Amit Saxena, Paul Klekotka, Peter Chen, Gourab Datta, Ariel Kay, Josh Poorbaugh, Mark J. Mulligan, William A. Fischer, Ying Grace Li, Karen L. Price, Patricia Brown-Augsburger, Ajay Nirula, Robert J. Benschop, Nadine Rouphael, Jenny Y. Chien, Jeffrey Fill, Michael Dougan
Publikováno v:
Clinical Pharmacology and Therapeutics
Therapeutics for patients hospitalized with coronavirus disease 2019 (COVID-19) are urgently needed during the pandemic. Bamlanivimab is a potent neutralizing monoclonal antibody that blocks severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2
Autor:
Kara W Chew, Paul Klekotka, Charles R Crain, Ajay Nirula, Manish Chandra Choudhary, Justin Ritz, Alan S. Perelson, Joan Dragavon, Joseph J. Eron, Alexander L. Greninger, Judith S. Currier, Carlee Moser, Ruian Ke, Robert W. Coombs, Michael Hughes, Urvi M. Parikh, Eric S. Daar, Davey M. Smith, James P. Flynn, David A. Wohl, Courtney V. Fletcher, Rinki Deo, Arzhang C Javan, Scott F. Sieg, Ruy M. Ribeiro, James Regan, Jonathan Z. Li
Publikováno v:
medRxiv
Resistance mutations to monoclonal antibody (mAb) therapy has been reported, but in the non-immunosuppressed population, it is unclear if in vivo emergence of SARS-CoV-2 resistance mutations alters either viral replication dynamics or therapeutic eff
Autor:
Andrew C. Adams, Jose Cardona, Barry Heller, Nicole L. Kallewaard, Jason Morris, Michael Durante, Bharat Mocherla, Richard E. Higgs, Valentina Stosor, Daniel Skovronsky, Joseph Boscia, Paul Klekotka, Princy Kumar, Imad Shawa, Robert L. Gottlieb, Ajay Nirula, Timothy R. Holzer, Lei Shen, Philip J. Ebert, Jacob Van Naarden, Gerard J. Oakley, Dipak R. Patel, Kenneth L. Custer, Andrew E. Schade, Janelle Sabo, Peter Chen, Gregory D. Huhn
Publikováno v:
JAMA. 325(7)
Importance: Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19. Objective: To determine the effect of bamlanivimab monotherapy and combination therapy with bamlani
Autor:
Jeannie Chao, Ajay Nirula, Lai Shan Melanie Chan, Won Park, William Barchuk, Alan Kivitz, Jennifer Witcher, Anna Dudek, Alberto Spindler, Akira Sagawa, Mark C. Genovese
Publikováno v:
The Journal of rheumatology. 48(7)
Objective.To evaluate the efficacy and safety of poseltinib (formerly LY3337641/HM71224), an irreversible covalent inhibitor of Bruton’s tyrosine kinase in a 2-part, phase II trial (RAjuvenate; ClinicalTrials.gov: NCT02628028) in adults with active
Autor:
Myron S, Cohen, Ajay, Nirula, Mark J, Mulligan, Richard M, Novak, Mary, Marovich, Catherine, Yen, Alexander, Stemer, Stockton M, Mayer, David, Wohl, Blair, Brengle, Brian T, Montague, Ian, Frank, Russell J, McCulloh, Carl J, Fichtenbaum, Brad, Lipson, Nashwa, Gabra, Julio A, Ramirez, Christine, Thai, Wairimu, Chege, Margarita M, Gomez Lorenzo, Nirupama, Sista, Jennifer, Farrior, Meredith E, Clement, Elizabeth R, Brown, Kenneth L, Custer, Jacob, Van Naarden, Andrew C, Adams, Andrew E, Schade, Matan C, Dabora, Jack, Knorr, Karen L, Price, Janelle, Sabo, Jay L, Tuttle, Paul, Klekotka, Lei, Shen, Daniel M, Skovronsky, George, Taffet
Publikováno v:
JAMA. 326:46
IMPORTANCE Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, m
Autor:
Lai Shan (Melanie) Chan, Jeannie Chao, Anna Dudek, Ajay Nirula, Akira Sagawa, Alan Kivitz, William Barchuk, Mark C. Genovese, Alberto Spindler, Won Park
Publikováno v:
SATURDAY, 15 JUNE 2019.
Background LY3337641 is an irreversible covalent inhibitor of Bruton’s tyrosine kinase (BTK), a key signaling molecule in the B-cell-receptor and Fc-receptor pathways and mediator of B-cell– and myeloid-cell–dependent inflammatory arthritis.1,2
Autor:
Chris B. Russell, Mayte Suárez-Fariñas, Lewis Tomalin, Sandra Garcet, Hanne Norsgaard, David Adrian Ewald, James G. Krueger, Ajay Nirula, Paul Klekotka
Publikováno v:
The Journal of allergy and clinical immunology. 145(3)
Background IL-17 antagonists induce impressive clinical benefits in psoriasis, but it is unknown to what extent cellular and molecular psoriasis characteristics are suppressed by a clinically relevant dose/schedule of any IL-17-receptor antagonist. O
Autor:
Ajay Nirula, Philip J. Mease, J. Feng, Hema N. Viswanathan, Ngozi Erondu, Alex Mutebi, Mark C. Genovese, Dina Chau
Publikováno v:
The Journal of Rheumatology. 43:343-349
Objective.To evaluate the effect of brodalumab on psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory (PSI) in patients with psoriatic arthritis (PsA).Methods.This prespecified analysis of a phase II study (NCT01516957) evaluated
Autor:
Alice B. Gottlieb, James G. Krueger, Ajay Nirula, Gregory Kricorian, Darryl Toth, Andrew Blauvelt, Kim A. Papp, Joanne Li, Kristian Reich, Carle Paul, Diamant Thaçi, Cassandra E Milmont, Richard G. Langley, Chris B. Russell, Paul Klekotka, W. Baran, Chantal Bolduc, J. Cather
Publikováno v:
The British journal of dermatology. 175(2)
SummaryBackground The interleukin-17 cytokine family plays a central role in psoriasis pathogenesis. Objectives To evaluate the efficacy and safety of brodalumab, a human anti-interleukin-17 receptor antibody, in treating patients with moderate-to-se